#Vienna #Austria #Alpha-9 Oncology #GRPR Imaging #EANM 2026

Alpha-9 Oncology's Milestone at EANM 2026

Alpha-9 Oncology Inc., a pioneering firm focused on radiotherapeutic solutions, has announced that it will showcase its latest data on 68Ga-A9-6217, a novel imaging compound targeting the gastrin-releasing peptide receptor (GRPR). This significant presentation is scheduled for the 2026 European Association of Nuclear Medicine (EANM) Annual Congress in Vienna, Austria, taking place from October 17-21, 2026.

The upcoming oral presentation will emphasize the role of 68Ga-A9-6217 in medical imaging, particularly for patients diagnosed with GRPR-expressing tumors. The presentation is expected to draw a wide audience from the field of nuclear medicine, reflecting the growing interest in targeted imaging techniques that enhance patient management in oncology.

Presentation Details

The titled presentation, "A Phase 1 Study Investigating the Safety, Biodistribution, and Dosimetry of [68Ga]Ga-A9-6217 in Participants with Select Advanced or Metastatic Solid Tumors", will entail a case series of patients who were evaluated with this compound. The details include:

• - Date/Time: Wednesday, October 21, 2026
• - Presentation Number: OP-877
• - Location: Hall C, Vienna

This pioneering study aims to provide insights into the biodistribution of 68Ga-A9-6217, further contributing to the understanding of its safety profile and potential therapeutic implications for patients with specific solid tumors, including HR+/HER2- breast cancer.

Company Background

Alpha-9 Oncology is at the forefront of developing targeted, next-generation cancer therapies. With a systematic approach to optimizing each treatment candidate, the company focuses its efforts on tailoring its compounds to the unique biological and biophysical characteristics of the tumor receptors they aim to target. Their unparalleled strategy integrates various components—such as binders, linkers, chelators, and radioisotope payloads—to formulate effective radiotherapeutics. This methodology is critical in ensuring maximal tumor retention while minimizing uptake in healthy tissues, ultimately aiming for a safer therapeutic window.

Currently, Alpha-9 is actively screening patients for its Phase 1 clinical trial, which evaluates the safety and tolerability of its dual radiotherapeutic agents: 225Ac-A9-0642 and 177Lu-A9-0631. These agents are being assessed for their efficacy in treating patients with GRPR-positive solid tumors, underscoring the importance of their imaging agent, 68Ga-A9-6217, in the patient selection process.

With the expected advancements from the EANM presentation, Alpha-9 Oncology is positioned to make significant strides in developing new diagnostic tools that could revolutionize how oncologists assess and treat cancers with GRPR markers.

For more information on Alpha-9 Oncology’s research and pipeline, please visit their website at www.a9oncology.com.